Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients

Does Fidaxomicin Therapy Reduce Spread of Clostridium Difficile?

NCT02461901 ·Status: COMPLETED

To Determine the Feasibility of a Fidaxomicin Study in Neonates and to Assess C. Difficile (Clostridium Difficile) Involvement in the Pathogenesis

NCT01533844 ·Status: TERMINATED

Prospective Observational Study of Clostridium Difficile Infection in Asian Pacific Countries

NCT02223715 ·Status: COMPLETED

Fidaxomicin to Prevent Clostridium Difficile Colonization

NCT01552668 ·Status: WITHDRAWN ·Phase: PHASE4

Personalized Needs in Clostridium Difficile Infections

NCT02573571 ·Status: COMPLETED

Impact of Oral Antibiotic Treatment on C. Difficile

NCT02057198 ·Status: COMPLETED ·Phase: PHASE4

LMN-201 for Prevention of C. Difficile Infection Recurrence

NCT05330182 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Vancomycin Taper to Prevent Recurrent Clostridioides Difficile

NCT07328971 ·Status: RECRUITING ·Phase: PHASE3

A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population

NCT02254967 ·Status: COMPLETED ·Phase: PHASE4

Clostridioides Difficile Controlled Human Infection Model

NCT06702345 ·Status: NOT_YET_RECRUITING ·Phase: NA

Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin

NCT01818141 ·Status: COMPLETED ·Phase: PHASE4

Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

NCT01591863 ·Status: COMPLETED ·Phase: PHASE2

Screening to Prophylax Against Clostridium Difficile Infection -

NCT02996487 ·Status: COMPLETED ·Phase: PHASE4

A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea

NCT00034294 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of DAV132 in Patients at High-Risk for Clostridium Difficile Infection (CDI)

NCT03710694 ·Status: COMPLETED ·Phase: NA

Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)

NCT04000555 ·Status: TERMINATED ·Phase: PHASE4

Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea

NCT01670149 ·Status: COMPLETED ·Phase: PHASE4

A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections

NCT02692651 ·Status: COMPLETED ·Phase: PHASE4

A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)

NCT02784002 ·Status: COMPLETED ·Phase: PHASE2

Study of CB-183,315 in Participants With Clostridium Difficile Infection

NCT01085591 ·Status: COMPLETED ·Phase: PHASE2

Observational Study of C. Diff in Post-Transplant Patients

NCT02747017 ·Status: COMPLETED

Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin

NCT05201079 ·Status: COMPLETED ·Phase: PHASE3

A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

NCT02218372 ·Status: COMPLETED ·Phase: PHASE3

Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease

NCT06794944 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics

NCT02951702 ·Status: COMPLETED ·Phase: PHASE4